How India Exports Imatinib to the World

In the United States, the Food and Drug Administration (FDA) has approved multiple Abbreviated New Drug Applications (ANDAs) for generic versions of imatinib, as listed in the FDA's Orange Book. These approvals have facilitated the entry of numerous Indian pharmaceutical companies into the U.S. market, contributing to the 24.3% share of imatinib exports to the United States. The regulatory pathway for these generics involves demonstrating bioequivalence to the reference listed drug, Glivec (imatinib mesylate), ensuring safety and efficacy. As of March 2026, there are no active import alerts related to imatinib, indicating compliance with FDA standards by Indian exporters.

In the European Union, the European Medicines Agency (EMA) has granted marketing authorizations for generic imatinib products. For instance, Imatinib Actavis received authorization on April 17, 2013, but the authorization was withdrawn on May 16, 2022, at the request of the marketing authorization holder for commercial reasons. Similarly, Imatinib Koanaa was authorized on September 22, 2021, with its authorization withdrawn on August 31, 2023. These withdrawals reflect market dynamics rather than regulatory concerns. The United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) aligns with EMA standards, requiring adherence to Good Manufacturing Practice (GMP) guidelines for marketing authorizations.

Imatinib is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its importance in treating CML and GIST. The 22nd edition, updated in September 2021, lists imatinib as an essential medicine. This inclusion emphasizes the global recognition of imatinib's therapeutic value and the necessity for its accessibility. Compliance with international pharmacopoeia standards, such as the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), is crucial for ensuring the quality and efficacy of imatinib formulations.

In India, imatinib is classified under Schedule H of the Drugs and Cosmetics Act, requiring a prescription for its dispensation. The National Pharmaceutical Pricing Authority (NPPA) regulates its price under the Drug Price Control Order (DPCO). As of March 2026, the ceiling price for imatinib is set to ensure affordability while maintaining quality. For exports, the Directorate General of Foreign Trade (DGFT) mandates a No Objection Certificate (NOC) to ensure compliance with international standards and to monitor the quality of pharmaceutical exports.

The primary patent for imatinib mesylate expired in 2016, leading to increased generic competition globally. This expiration has allowed numerous Indian pharmaceutical companies to manufacture and export generic imatinib, contributing to the substantial export figures observed between 2022 and 2026.

In June 2022, the EMA announced the withdrawal of the marketing authorization for Imatinib Actavis, following the request of the marketing authorization holder due to commercial reasons. This reflects the competitive landscape and market dynamics affecting generic imatinib products in the EU.

In August 2023, the EMA withdrew the marketing authorization for Imatinib Koanaa, also at the request of the marketing authorization holder, indicating ongoing shifts in the European market for generic imatinib.

In January 2026, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for Iclusig (ponatinib), recommending its use in adult patients with chronic myeloid leukemia resistant to prior therapies, including imatinib. This development introduces additional therapeutic options in the treatment landscape.

In February 2026, the NPPA revised the ceiling price for imatinib under the DPCO, reflecting efforts to balance affordability with the sustainability of pharmaceutical manufacturing in India.

In March 2026, the WHO updated its Model List of Essential Medicines, reaffirming the inclusion of imatinib, which underscores its continued significance in global health.

These developments highlight the dynamic regulatory and market environment surrounding imatinib, influencing both its global availability and the strategic decisions of Indian exporters.

Imatinib, a critical medication for chronic myeloid leukemia, is predominantly manufactured in India. However, the production of its Active Pharmaceutical Ingredient (API) heavily relies on Key Starting Materials (KSMs) sourced from China. This dependency exposes the supply chain to vulnerabilities stemming from geopolitical tensions, trade restrictions, and environmental regulations in China. Notably, in recent years, several Chinese API manufacturers have been shut down due to non-compliance with pollution norms, leading to supply disruptions and cost escalations.

The COVID-19 pandemic further highlighted the fragility of this reliance. During the crisis, disruptions in Chinese exports led to significant shortages of APIs in India, underscoring the need for a more self-reliant pharmaceutical supply chain. Despite India's position as the third-largest manufacturer of APIs globally, the country continues to import approximately 67% of its bulk drugs from China, emphasizing the critical nature of this dependency.

Our proprietary trade data indicates that the top five Indian exporters of Imatinib account for 81.2% of total exports, with CIPLA LIMITED alone contributing 36.4%. This high supplier concentration poses a significant risk; any operational or regulatory issues affecting these key players could disrupt the global supply of Imatinib.

To mitigate such risks, the Indian government introduced the Production Linked Incentive (PLI) scheme in 2020, aiming to boost domestic manufacturing of APIs and reduce dependence on imports. While this initiative has led to increased investment in API production, the transition to self-sufficiency is gradual, and the industry remains vulnerable to supply chain disruptions in the interim.

Recent geopolitical events have further strained the Imatinib supply chain. In February 2026, escalating conflicts in the Middle East led to attacks on vessels in the Strait of Hormuz, a critical shipping route. Major shipping companies, including Maersk and MSC, suspended transits through the strait, causing significant delays and increased shipping costs. Additionally, the Red Sea has experienced heightened threats to commercial shipping, further complicating logistics.

These disruptions have had a cascading effect on the pharmaceutical industry. For instance, the closure of the Strait of Hormuz has led to supply shocks in energy markets, impacting the production and transportation of APIs. Furthermore, the FDA has reported intermittent shortages of Imatinib at the pharmacy level, attributed to these logistical challenges.

• Diversify API Sourcing: Encourage the development of alternative sources for KSMs and APIs beyond China to reduce dependency and enhance supply chain resilience.

• Strengthen Domestic Manufacturing: Accelerate the implementation of the PLI scheme and provide additional incentives to bolster domestic API production capabilities.

• Enhance Supplier Base: Promote the growth of smaller and mid-sized pharmaceutical companies to reduce supplier concentration and mitigate single-source risks.

• Develop Contingency Logistics Plans: Establish alternative shipping routes and logistics strategies to navigate geopolitical disruptions effectively.

• Monitor Regulatory Compliance: Implement robust monitoring systems to ensure compliance with environmental and safety regulations, preventing potential shutdowns and supply interruptions.

RISK_LEVEL: HIGH